InvestorsHub Logo

Ringrock

02/06/16 8:14 AM

#139169 RE: F1ash #139159

great morning read... thanks for the links, solid DD!

2020 cancer moonshot... sounds like a plan(as she busts out a refrain of ("I can see clearly now the rain is gone...")

tombrady12nh

02/06/16 9:50 AM

#139170 RE: F1ash #139159

From post 139169
compound. In addition to its p53 restorative property, Welsh and his colleague’s at MD Anderson have found that Kevetrin also behaves like a checkpoint inhibitor. Two PD1-inhibiting drugs, Keytruda and Opdivo, were approved in 2015 for treatment of metastatic lung cancer and while they are effective approximately 20% of the time, they each cost about $150,000 annually.

frrol

02/06/16 5:26 PM

#139177 RE: F1ash #139159

Kevetrin is not a "checkpoint inhibitor" in any way. That term specifically describes inhibiting the blocking of the binding of immune system cells to pathogens. Kevetrin's MOA is completely different, having nothing to do with the immune system. Kevetrin removes, if you will, the inhibition of programmed cell death. Hope that is helpful.

(PS there are cell life cycle "checkpoints", so you can think about Kevetrin as a cell life cycle checkpoint enabler.)